Trial · NCT03733444
Results by group167
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 167
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Annual Rate of Decline in Forced Vital Capacity (FVC) up to Week 52 | GLPG1690, 600 mg | -173.8 | Standard Error 18.04 | mL/year | |
| Annual Rate of Decline in Forced Vital Capacity (FVC) up to Week 52 | GLPG1690, 200 mg | -174.9 | Standard Error 17.65 | mL/year | |
| Annual Rate of Decline in Forced Vital Capacity (FVC) up to Week 52 | Placebo | -176.6 | Standard Error 17.74 | mL/year | |
| Percentage of Participants With Disease Progression Up to 52 Weeks | GLPG1690, 600 mg | 23.9 | Percentage of participants | ||
| Percentage of Participants With Disease Progression Up to 52 Weeks | GLPG1690, 200 mg | 23.1 | Percentage of participants | ||
| Percentage of Participants With Disease Progression Up to 52 Weeks | Placebo | 22.1 | Percentage of participants | ||
| Percentage of Participants With Respiratory-Related Hospitalization Until End of Study (EoS) | GLPG1690, 600 mg | 13.5 | Percentage of participants | ||
| Percentage of Participants With Respiratory-Related Hospitalization Until End of Study (EoS) | GLPG1690, 200 mg | 10.8 | Percentage of participants | ||
| Percentage of Participants With Respiratory-Related Hospitalization Until End of Study (EoS) | Placebo | 6.6 | Percentage of participants | ||
| Change From Baseline in St.George's Respiratory Questionnaire (SGRQ) Total Score at Week 52 | GLPG1690, 600 mg | 4.6 | Standard Error 1.13 | Score on a scale | |
| Change From Baseline in St.George's Respiratory Questionnaire (SGRQ) Total Score at Week 52 | GLPG1690, 200 mg | 4.3 | Standard Error 1.08 | Score on a scale | |
| Change From Baseline in St.George's Respiratory Questionnaire (SGRQ) Total Score at Week 52 | Placebo | 4.7 | Standard Error 1.10 | Score on a scale | |
| Annual Rate of Decline of FVC Until EoS | GLPG1690, 600 mg | -179.5 | Standard Error 15.96 | mL/year | |
| Annual Rate of Decline of FVC Until EoS | GLPG1690, 200 mg | -174.4 | Standard Error 15.63 | mL/year | |
| Annual Rate of Decline of FVC Until EoS | Placebo | -182.4 | Standard Error 15.72 | mL/year | |
| Percentage of Participants With Disease Progression Until EoS | GLPG1690, 600 mg | 31.7 | Percentage of participants | ||
| Percentage of Participants With Disease Progression Until EoS | GLPG1690, 200 mg | 27.7 | Percentage of participants | ||
| Percentage of Participants With Disease Progression Until EoS | Placebo | 26.7 | Percentage of participants | ||
| Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 100 | GLPG1690, 600 mg | 12.1 | 95% Confidence Interval 3.0 to 21.2 | Score on a scale | |
| Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 100 | GLPG1690, 200 mg | 14.8 | 95% Confidence Interval 4.6 to 25.1 | Score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03733444/results